Craig Hallum initiated coverage on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a research note published on Wednesday morning, Marketbeat reports. The brokerage issued a buy rating and a $11.00 price target on the stock.
Several other equities research analysts have also commented on SABS. HC Wainwright reiterated a buy rating and issued a $6.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, August 12th. Oppenheimer reaffirmed an outperform rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a report on Thursday, September 12th. Finally, Chardan Capital reaffirmed a buy rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a report on Monday, September 9th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of Buy and a consensus target price of $12.40.
Read Our Latest Report on SABS
SAB Biotherapeutics Price Performance
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.34. The company had revenue of $0.26 million during the quarter. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%. As a group, analysts anticipate that SAB Biotherapeutics will post -3.59 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. BVF Inc. IL purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at $6,310,000. Commodore Capital LP bought a new position in SAB Biotherapeutics in the 4th quarter worth $1,259,000. Finally, First PREMIER Bank purchased a new stake in SAB Biotherapeutics in the second quarter worth about $60,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.
Recommended Stories
- Five stocks we like better than SAB Biotherapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- NYSE Stocks Give Investors a Variety of Quality Options
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- 5 Top Rated Dividend Stocks to Consider
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.